Axsome Therapeutics, Inc. $AXSM Shares Bought by Swiss National Bank

Swiss National Bank grew its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 6.9% during the second quarter, HoldingsChannel reports. The firm owned 65,200 shares of the company’s stock after buying an additional 4,200 shares during the period. Swiss National Bank’s holdings in Axsome Therapeutics were worth $6,806,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. BVF Inc. IL grew its holdings in Axsome Therapeutics by 21.8% during the 1st quarter. BVF Inc. IL now owns 1,690,221 shares of the company’s stock valued at $197,130,000 after purchasing an additional 302,157 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 5.8% during the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock worth $103,303,000 after acquiring an additional 54,600 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Axsome Therapeutics by 23.8% in the first quarter. Invesco Ltd. now owns 857,001 shares of the company’s stock worth $99,952,000 after acquiring an additional 164,537 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Axsome Therapeutics by 4.5% in the first quarter. Wellington Management Group LLP now owns 703,279 shares of the company’s stock worth $82,023,000 after acquiring an additional 30,122 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Axsome Therapeutics in the first quarter valued at about $48,185,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and issued a $154.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 4th. B. Riley began coverage on shares of Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target on the stock. Royal Bank Of Canada raised their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Finally, Mizuho upped their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $179.88.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $151.56 on Monday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51. Axsome Therapeutics, Inc. has a 12 month low of $75.56 and a 12 month high of $152.94. The company has a fifty day moving average price of $131.99 and a two-hundred day moving average price of $117.56. The company has a market cap of $7.64 billion, a PE ratio of -29.89 and a beta of 0.50.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The business had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. The business’s quarterly revenue was up 63.2% on a year-over-year basis. Research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 45,783 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $114.48, for a total transaction of $5,241,237.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roger Jeffs sold 13,464 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $123.68, for a total value of $1,665,227.52. Following the sale, the director owned 57,510 shares in the company, valued at $7,112,836.80. The trade was a 18.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 350,577 shares of company stock worth $43,803,199 over the last ninety days. Company insiders own 22.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.